Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
Objective: To compare the treatment costs of insulin glargine (IG; Lantus®) to detemir (ID; Levemir®), both combined with bolus insulin aspart (NovoRapid®) in type 2 diabetes (T2D) in Germany. Methods: Cost comparison was based on data of a 1-year randomised controlled trial [1]. IG was administered...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | deu |
| Published: |
German Medical Science GMS Publishing House
2010-01-01
|
| Series: | GMS German Medical Science |
| Subjects: | |
| Online Access: | http://www.egms.de/en/journals/gms/2010-8/000106.shtml |
| _version_ | 1830460728008507392 |
|---|---|
| author | Dippel, Franz-Werner Dietrich, Eva Susanne Pscherer, Stefan Neilson, Aileen Rae |
| author_facet | Dippel, Franz-Werner Dietrich, Eva Susanne Pscherer, Stefan Neilson, Aileen Rae |
| author_sort | Dippel, Franz-Werner |
| collection | DOAJ |
| description | Objective: To compare the treatment costs of insulin glargine (IG; Lantus®) to detemir (ID; Levemir®), both combined with bolus insulin aspart (NovoRapid®) in type 2 diabetes (T2D) in Germany. Methods: Cost comparison was based on data of a 1-year randomised controlled trial [1]. IG was administered once daily and ID once (57% of patients) or twice daily (43%) according to treatment response. At the end of the trial, mean daily basal insulin doses were 0.59 U/kg (IG) and 0.82 U/kg (ID). Aspart doses were 0.32 U/kg (IG) and 0.36 U/kg (ID). Costs were calculated from the German statutory health insurance (SHI) perspective using official 2008 prices. Sensitivity analyses were performed to test robustness of the results. Results: Annual basal and bolus insulin costs per patient were € 1,473 (IG) and € 1,940 (ID). The cost of lancets and blood glucose test strips were € 1,125 (IG) and € 1,286 (ID). Annual costs for needles were € 393 (IG) and € 449 (ID). The total annual cost per patient of administering IG was € 2,991 compared with € 3,675 for ID, translating into a 19% annual cost difference of € 684/patient. Base case results were robust to varying assumptions for insulin dose, insulin price, change in weight and proportion of ID once daily administrations. Conclusion: IG and ID basal-bolus regimes have comparative safety and efficacy, based on the Hollander study, IG however may represent a significantly more cost saving option for T2D patients in Germany requiring basal-bolus insulin analogue therapy with potential annual cost savings of € 684/patient compared to ID. |
| first_indexed | 2024-12-21T11:16:52Z |
| format | Article |
| id | doaj.art-706ae7b3b9484fcd984b1005e138c2c9 |
| institution | Directory Open Access Journal |
| issn | 1612-3174 |
| language | deu |
| last_indexed | 2024-12-21T11:16:52Z |
| publishDate | 2010-01-01 |
| publisher | German Medical Science GMS Publishing House |
| record_format | Article |
| series | GMS German Medical Science |
| spelling | doaj.art-706ae7b3b9484fcd984b1005e138c2c92022-12-21T19:05:53ZdeuGerman Medical Science GMS Publishing HouseGMS German Medical Science1612-31742010-01-018Doc17Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in GermanyDippel, Franz-WernerDietrich, Eva SusannePscherer, StefanNeilson, Aileen RaeObjective: To compare the treatment costs of insulin glargine (IG; Lantus®) to detemir (ID; Levemir®), both combined with bolus insulin aspart (NovoRapid®) in type 2 diabetes (T2D) in Germany. Methods: Cost comparison was based on data of a 1-year randomised controlled trial [1]. IG was administered once daily and ID once (57% of patients) or twice daily (43%) according to treatment response. At the end of the trial, mean daily basal insulin doses were 0.59 U/kg (IG) and 0.82 U/kg (ID). Aspart doses were 0.32 U/kg (IG) and 0.36 U/kg (ID). Costs were calculated from the German statutory health insurance (SHI) perspective using official 2008 prices. Sensitivity analyses were performed to test robustness of the results. Results: Annual basal and bolus insulin costs per patient were € 1,473 (IG) and € 1,940 (ID). The cost of lancets and blood glucose test strips were € 1,125 (IG) and € 1,286 (ID). Annual costs for needles were € 393 (IG) and € 449 (ID). The total annual cost per patient of administering IG was € 2,991 compared with € 3,675 for ID, translating into a 19% annual cost difference of € 684/patient. Base case results were robust to varying assumptions for insulin dose, insulin price, change in weight and proportion of ID once daily administrations. Conclusion: IG and ID basal-bolus regimes have comparative safety and efficacy, based on the Hollander study, IG however may represent a significantly more cost saving option for T2D patients in Germany requiring basal-bolus insulin analogue therapy with potential annual cost savings of € 684/patient compared to ID.http://www.egms.de/en/journals/gms/2010-8/000106.shtmlinsulin glargineinsulin detemirbasal insulintype 2 diabetescost analysis |
| spellingShingle | Dippel, Franz-Werner Dietrich, Eva Susanne Pscherer, Stefan Neilson, Aileen Rae Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany GMS German Medical Science insulin glargine insulin detemir basal insulin type 2 diabetes cost analysis |
| title | Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany |
| title_full | Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany |
| title_fullStr | Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany |
| title_full_unstemmed | Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany |
| title_short | Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany |
| title_sort | cost comparison of insulin glargine with insulin detemir in a basal bolus regime with mealtime insulin aspart in type 2 diabetes in germany |
| topic | insulin glargine insulin detemir basal insulin type 2 diabetes cost analysis |
| url | http://www.egms.de/en/journals/gms/2010-8/000106.shtml |
| work_keys_str_mv | AT dippelfranzwerner costcomparisonofinsulinglarginewithinsulindetemirinabasalbolusregimewithmealtimeinsulinaspartintype2diabetesingermany AT dietrichevasusanne costcomparisonofinsulinglarginewithinsulindetemirinabasalbolusregimewithmealtimeinsulinaspartintype2diabetesingermany AT pschererstefan costcomparisonofinsulinglarginewithinsulindetemirinabasalbolusregimewithmealtimeinsulinaspartintype2diabetesingermany AT neilsonaileenrae costcomparisonofinsulinglarginewithinsulindetemirinabasalbolusregimewithmealtimeinsulinaspartintype2diabetesingermany |